(Q44194141)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12399946%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

title

A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12399946%20AND%20SRC:MED&resulttype=core&format=json

major depressive disorder

14 December 2019

main subject

patient

0 references

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12399946%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

author name string

Hauser P

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12399946%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

Khosla J

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12399946%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

Aurora H

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12399946%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

Laurin J

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12399946%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

Hill J

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12399946%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

Gulati M

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12399946%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

Thornton AJ

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12399946%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

Schultz RL

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12399946%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

Valentine AD

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12399946%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

Meyers CA

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12399946%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

Howell CD

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12399946%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

language of work or name

English

0 references

publication date

1 January 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12399946%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12399946%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12399946%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

page(s)

942-947

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12399946%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12399946%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.mp.4001119

14 December 2019

exact match

0 references

cites work

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001119

21 January 2018

Doing battle with HCV.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001119

Epidemiology of hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001119

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001119

Neuropsychiatric toxicity associated with cytokine therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001119

Hepatitis C and depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001119

Reduced quality of life in patients with chronic hepatitis C: effects of interferon treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001119

Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001119

Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001119

Hepatitis C, interferon alfa, and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001119

Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001119

Psychiatric complications of long-term interferon alfa therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001119

Paroxetine for the prevention of depression induced by high-dose interferon alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001119

Citalopram in the treatment of depression and other potential uses in psychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001119

An Inventory for Measuring Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001119

Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001119

Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001119

7 January 2021

Psychiatric side effects of interferon

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001119

7 January 2021

Successful treatment of interferon alfa-induced mood disorder with nortriptyline

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001119

7 January 2021

Five cases of interferon-alpha-induced depression treated with antidepressant therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001119

7 January 2021

Prophylactic treatment of depression induced by interferon-alpha

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001119

7 January 2021

Self-reported depressive symptoms that differentiate recurrent-episode major depression from dysthymic disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001119

7 January 2021

Suicide associated with alfa-interferon therapy for chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001119

7 January 2021

Identifiers

DOI

10.1038/SJ.MP.4001119

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12399946%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

1 reference